Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Pharmacotherapeutic considerations in women with multiple sclerosis

    Research output: Contribution to journalReviewpeer-review

  2. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Research output: Contribution to journalReviewpeer-review

  3. Treatment of adult short bowel syndrome patients with teduglutide

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Therapeutic management of type 1 diabetes before and during pregnancy

    Research output: Contribution to journalJournal articleResearch

  5. Treating tension-type headache -- an expert opinion

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations
INTRODUCTION: Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irinotecan provides impressive response rates (RR), it is still uncertain if this treatment translates into improved clinical benefit in GBM patients. AREAS COVERED: This review discusses the clinical efficacy, safety and difficulties regarding response evaluation when treating with BVZ and CPT-11 in recurrent GBM. Particular attention is placed on the literature and a discussion on whether treatment with BVZ and CPT-11 improves clinical outcome. Antiangiogenic treatment has led to difficulties when evaluating objective response by the conventional MacDonald criteria. In the present paper the authors discuss selected key aspects of this treatment modality. A literature search was performed using PubMed in February 2011. EXPERT OPINION: BVZ + irinotecan leads to high RR and to an increased 6-month progression-free survival. However, no improvement in median overall survival has been observed compared with conventional chemotherapy. Nevertheless, the GBM patients who respond to treatment with BVZ and irinotecan have survived significantly longer than non-responders, indicating that it could be beneficial for a selection of patients to receive this treatment.
Original languageEnglish
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number5
Pages (from-to)825-33
Number of pages9
ISSN1465-6566
DOIs
Publication statusPublished - 1 Apr 2011

    Research areas

  • Antibodies, Monoclonal, Antineoplastic Agents, Brain Neoplasms, Camptothecin, Glioblastoma, Humans, Middle Aged, Recurrence, Survival Analysis

ID: 32428129